Loading viewer...
investor_presentation
Format: PDF investor_presentation
8 Q1 2022 Earnings Supplemental Materials April 29, 2022 1
Q1 2022 Earnings Supplemental Materials
Forward- Looking Information
This presentation contains forward- looking statements and information. Statements that are not historical facts, including stat ements about our beliefs and
expectations, are forward- looking statements. Forward- looking statements include statements preceded by, followed by or that include the words “may,” “could,”
“would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “estimate,” “target,” “project,” “intend” and similar expressions. These statements include, among others,
statements regarding our expected performance, anticipated returns on our investments, financing and hedging strategies, and means to implement those
strategies, and actual or anticipated actions of the Federal Reserve (the “Fed”), and the impact of those actual or anticipat ed actions on the Company.
The forward- looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently
available to us. You should not place undue reliance on these forward- looking statements. These beliefs, assumptions and expectations can change as a result of
many possible events or factors, not all of which are known to us. Some of these factors are described under the caption ‘‘Ri sk Factors’’ in our Annual Report on
Form 10- K. If a change occurs, our business, financial condition, liquidity and results of operations may vary materially from t hose expressed in our forward- looking
statements. Any forward- looking statement speaks only as of the date on which it is made. New risks and uncertainties arise from time to time, and it is impossible
for us to predict those events or how they may affect us. Except as required by law, we are not obligated to, and do not intend to, update or revise any forward
investor_presentation
Seven & i Holdings
Karyopharm Therapeutics Investor Presentation — February 2020
investor_presentationinvestor_presentation
40 Pages
Karyopharm Therapeutics Inc.
looking statements, whether as a result of new information, future events or otherwise.
Financial Highlights for the Quarter Ended March 31, 2022 4 -6
Market Developments 7 -15
Financial Results 16 -21
Portfolio Characteristics, Credit Counterparties & Hedge Positions 22 -27
3Slide(s)Financial Highlights for the Quarter Ended March 31, 2022
•Net loss per share of $0.84
•Net earnings per share of $0.20, excluding realized and unrealized gains/(losses) on RMBS and derivative instruments,
including net interest expense on interest rate swaps (See page 2 9for reconciliation of this non- GAAP measure to earnings
•Loss of $1.04 per share from net realized and unrealized losses on RMBS and derivative instruments, including net interest expense on interest rate swaps
•Book value per share of $3.34 at March 31, 2022 versus $4.34 atDecember 31, 2021
•In Q1 2022, the Company declared and subsequently paid $0.155 per share in dividends. Since its initial public offering, the Company has declared $12.635 in dividends per share, including the dividends declared in April 2022
•Total economic loss of $0.845 per share, or (19.5%), for the quarter
Preview truncated — download the full document for the complete content.
presentation